H.C. Wainwright Believes Amarin (AMRN) Won’t Stop Here


H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Amarin (AMRN) today and set a price target of $51. The company’s shares closed yesterday at $21.18, close to its 52-week high of $23.34.

Fein wrote:

“Our PT of $51 is based on equally weighted average of: (a) $41.37/share, as a 25x multiple of taxed and diluted FY29 GAAP EPS of $6.6c9 discounted back to and (b) an NPV of $60.99/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) Vascepa commercial ramp-up and/or peak sales not meeting our projections; and (2) further competitive disruption of the omega-3 market by branded drugs or generics and/ or OTC supplements beyond our model.”

According to TipRanks.com, Fein is a 5-star analyst with an average return of 9.3% and a 48.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.

Amarin has an analyst consensus of Strong Buy, with a price target consensus of $30.20, a 42.6% upside from current levels. In a report issued on February 15, Cantor Fitzgerald also maintained a Buy rating on the stock with a $35 price target.

See today’s analyst top recommended stocks >>

Based on Amarin’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $24.51 million. In comparison, last year the company had a GAAP net loss of $22.77 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It’s product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale.

Read More on AMRN:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts